1. Home
  2. TAP vs SYRE Comparison

TAP vs SYRE Comparison

Compare TAP & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Molson Coors Beverage Company Class B

TAP

Molson Coors Beverage Company Class B

HOLD

Current Price

$42.21

Market Cap

8.5B

ML Signal

HOLD

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

HOLD

Current Price

$95.49

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TAP
SYRE
Founded
1873
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
8.5B
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
TAP
SYRE
Price
$42.21
$95.49
Analyst Decision
Hold
Strong Buy
Analyst Count
17
12
Target Price
$48.94
$85.08
AVG Volume (30 Days)
2.7M
795.7K
Earning Date
04-30-2026
05-08-2026
Dividend Yield
4.53%
N/A
EPS Growth
N/A
N/A
EPS
2.03
N/A
Revenue
$11,723,800,000.00
N/A
Revenue This Year
$0.85
N/A
Revenue Next Year
$0.17
N/A
P/E Ratio
$20.69
N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.04
$14.51
52 Week High
$54.82
$110.18

Technical Indicators

Market Signals
Indicator
TAP
SYRE
Relative Strength Index (RSI) 51.90 38.06
Support Level $40.53 $66.78
Resistance Level $43.65 $106.10
Average True Range (ATR) 1.01 4.57
MACD -0.04 -1.11
Stochastic Oscillator 46.34 12.26

Price Performance

Historical Comparison
TAP
SYRE

About TAP Molson Coors Beverage Company Class B

Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling, and ranks as the second-largest beer maker in both value and volume in the US, Canada, and the United Kingdom. Through licensing agreements, it also brews and distributes beer and nonbeer beverage categories under partner brands from Heineken, Anheuser-Busch InBev, Asahi, Fever-Tree, and Coca-Cola. North America remains its largest market, accounting for nearly 80% of total revenue.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: